摘要
目的回顾性比较分析原发性硬化性胆管炎伴溃疡性结肠炎和克罗恩病患者的相关指标,为临床诊治提供依据。方法选取2005年1月至2015年12月间我院收治的原发性硬化性胆管炎患者257例,原发性硬化性胆管炎伴克罗恩病患者72例。回顾性分析这两组患者的病历资料等信息并做统计分析。结果两组患者的吸烟史、参与的胆总管数、生物制剂、结肠切除术、不典型增生、结肠癌、进展不良和/或癌组间比较具有统计学差异。CD患者与结肠切除术风险降低密切相关;Mayo评分是结肠切除术的保护性因素;而UC或CD诊断为PSC前持续时间、进展不良和/或癌及结肠癌是结肠切除术的危险因素。CD患者与结肠不典型增生和/或癌风险降低密切相关;而UC或CD诊断为PSC前持续时间是结肠不典型增生和/或癌的危险因素。结论原发性硬化性胆管炎伴克罗恩病患者结肠切除术、结肠不典型增生及结肠癌风险比原发性硬化性胆管炎伴溃疡性结肠炎患者显著降低。
Objective Retrospective comparative analysis of patients with primary sclerosing cholangitis （PSC） with ulcerative colitis and Crohn＇s disease, in order to provide the basis for clinical diagnosis and treatment. Methods We selected 257 patients with primary sclerosing cholangitis who were admitted in our department between January 2005 and December 2015. Among them, there were 160 male, 97 female, mean age was 41.2 ＋ 15.2 years. There were 185 patients diagnosed with ulcerative colitis （UC） and 72 cases with Crohn＇s disease （CD）. By retrospective analysis of medical records of patients, following aspects were studied： age, gender, height, weight, BMI, intrahepatic bile duct, extrahepatic bile duct, smoking history, drinking history, Mayo score, bilirubin, albumin, triglyceride, total cholesterol, high density lipoprotein, low density lipoprotein, low density lipoprotein, C-reactive protein （hsCRP） and aspartate aminotransferase, urea nitrogen, creatinine, UC or CD before the diagnosis of PSC duration, ursodeoxycholic acid, ursodeoxycholic acid dose, 6-mercaptopurine, azathioprine / biological agents, corticosteroids, 5-amino salicylic acid, colectomy, atypical hyperplasia, carcinoma of colon, progress and bad and / or colon cancer, bile duct cancer information and statistical analysis. Results Smoking history, the participation of common bile duct number, biological preparation, colon resection, atypical hyperplasia, colon cancer, bad progress and / or knot colorectal cancer were all statistically significant between two groups （P = 0.001, P = 0.027; P 〈 0.001, P = 0.003, P = 0.015; P = 0.001; P = 0.002）. Cancer risk in PSC patients was decreased in CD patients with colon resection （OR=0.72, 95% CI=0.38-0.94, P = 0.034）. Mayo score was protective factors （OR=0.35, 95% CI=0.16-0.58, P = 0.025）; and the misdiagnosis of UC or CD for PSC with extended time （OR = 1.46, 95% CI=1.26-3.26, P = 0.006）, bad progress （OR=3.77, 95% CI=3.15-8.74, P 〈 0.001）, and colon cancer （
出处
《标记免疫分析与临床》
CAS
2016年第7期797-801,共5页
Labeled Immunoassays and Clinical Medicine
